6-K: Dupixent sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid and Sanofi and CD&R Sign Opella Share Purchase Agreement

Feb 20 12:22 ET

SCHEDULE 13G/A: Others

Feb 14 12:19 ET

13F-HR: Information required of institutional investment managers pursuant to Section 13(f)

Feb 14 11:30 ET

IRANNOTICE: IRANNOTICE

Feb 13 14:14 ET

20-F: FY2024 Annual Report

Feb 13 13:49 ET

6-K: Update on Extraintestinal Pathogenic E. coli Vaccine Phase 3 Clinical Study

Feb 13 12:24 ET

6-K: Execution of a Share Buyback Agreement for up to €2 Billion

Feb 7 11:15 ET

6-K: Sarclisa Is the First Anti-CD38 Treatment in Combination with Standard-of-Care VRd Approved in China for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant and Sanofi Announces Buy Back of Shares from L'Oréal

Feb 3 10:17 ET

6-K: Q4 Sales Growth of 10.3%, 2024 Business EPS Guidance Exceeded, And Strong Business EPS Rebound Expected in 2025

Jan 30 09:56 ET

6-K: Opella Reaches Study Milestone for Cialis and Sarclisa Approved in the EU as the First Anti-CD38 Therapy in Combination with Standard-of-Care VRd to Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Jan 24 06:08 ET

6-K: New Sarclisa Subcutaneous Formulation Met Co-Primary Endpoints in the IRAKLIA Phase 3 Study in Multiple Myeloma and Sarclisa Obtains First Approval in China for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma

Jan 14 08:42 ET

6-K: Jean-Paul Kress to join Sanofi's Board of Directors and Sanofi Initiates Phase 3 Program for PCV21 and Expands Collaboration with Sk Bioscience for Next-Generation Pneumococcal Conjugate Vaccines

Dec 23, 2024 14:11 ET

6-K: Tolebrutinib Designated Breakthrough Therapy by the FDA for Non-relapsing Secondary Progressive Multiple Sclerosis and Duvakitug Positive Phase 2b Results Demonstrate Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease

Dec 20, 2024 06:10 ET

6-K: Colletion of Recent Announcements

Dec 13, 2024 11:11 ET

6-K: Sarclisa Recommended for EU Approval by the CHMP to Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma and Dupixent sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria

Nov 18, 2024 12:26 ET

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)

Nov 7, 2024 14:53 ET

6-K: Dupixent Approved in the EU as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

Nov 7, 2024 11:38 ET

6-K: Dupixent Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI

Oct 31, 2024 07:00 ET

6-K: 15.7% Sales Growth Boosted by Earlier-Than-Anticipated Vaccine Sales; 2024 Business Eps Guidance Raised Due to Strong Business Performance

Oct 25, 2024 12:42 ET

6-K: Sanofi and Orano Join Forces to Develop Next-Generation Radioligand Medicines and Sanofi and CD&R Partner to Fuel Opella's Ambitions in Consumer Healthcare

Oct 21, 2024 11:50 ET